Neurogene Inc (NGNE) Stock Forecast & Price Target

Neurogene is supported by a strong balance sheet, with $225.4M in cash, cash equivalents, and short-term investments at June 30 and pro forma cash of about $360.2M after the follow-on offering, which extends runway into 1Q29 and reduces financing risk ahead of key milestones. Its lead program NGN-401 continues to show compelling fundamental progress, with 8/10 patients meeting the pivotal composite endpoint at 12 months, 10/10 improving on CGI-I and gaining developmental milestones, and 47 total milestones gained with no plateau through up to 30 months. Execution also appears credible, as submission-enabling CMC work is on schedule, PPQ runs are expected to complete by YE26, and safety at the 1E15 vg dose remains generally well tolerated across 35 treated patients.

Neurogene is a clinically focused biotech whose valuation rests heavily on NGN-401, but the investment case looks fragile because the DCF assumes only a 55% probability of approval, while the company’s own risks highlight safety concerns at the current clinical dose of 1E15 vg and the possibility of efficacy in the registrational trial falling well below the 80% observed to date. The broader fundamental profile is also weakened by regulatory uncertainty around whether the ongoing single-arm, natural history-controlled EMBOLDEN study can support a BLA submission, alongside commercialization hurdles from ICV administration and potential caregiver reluctance to use a one-time therapy in a non-degenerative disease. With a $1.8B EV based on a 13% discount rate and 1% terminal growth rate, and only 30.9M fully-diluted shares, the thesis remains exposed to development delays, unfavorable data, and long-term dilution risk, while upside from other programs is not modeled.